Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NEO | 8-K | neutral | 4/10 | NeoGenomics finalized a civil settlement with the DOJ for $9.8M, resolving a legacy investigation into consulting servic | Jul 20, 2026 |
| TXG | INST-CLUSTER | mixed | 6/10 | A mixed institutional cluster emerged in 10x Genomics during Q1 2026: 14 buyers (net adding $235M) and 13 sellers (net r | Jul 5, 2026 |
| ILMN | COURT-RULING | neutral | 5/10 | { "summary": "The court denied Illumina's motion to stay discovery in a patent infringement case brought by Element Bi | Jul 4, 2026 |
| BEAM | CLUSTER | mixed | 5/10 | A cluster of insider selling at Beam Therapeutics materialized over June 26-30, 2026, totaling $8.95M. The CEO exercised | Jul 2, 2026 |
| BEAM | CLUSTER | bearish | 4/10 | CEO John M. Evans exercised options and sold shares worth ~$1.26M, while 10% owner FMR LLC sold 251,488 shares (~$8.87M) | Jul 2, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Three Twist Bioscience insiders, including CEO Emily Leproust, sold a combined $203K in open-market transactions on June | Jun 25, 2026 |
| TWST | S-3ASR | neutral | 3/10 | Twist Bioscience filed an automatic shelf registration (S-3ASR) including a base prospectus for various securities and a | Jun 18, 2026 |
| TXG | 144 | neutral | 2/10 | Board member Shehnaaz Suliman (ultragenyx CFO) filed intent to sell 5,723 shares of TXG Class A common stock worth appro | Jun 16, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia reported additional positive Phase 3 HAELO results for lonvo-z (CRISPR gene editing candidate) in hereditary an | Jun 15, 2026 |
| ILMN | COURT-RULING | bullish | 7/10 | The California Supreme Court reversed the Court of Appeal in J.M. v. Illuminate Education, holding that plaintiff J.M. f | Jun 13, 2026 |
| NTLA | PRESS-RELEASE | bullish | 8/10 | Intellia presented additional positive Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE at EAACI 2026, with the manuscr | Jun 13, 2026 |
| FATE | INST-CLUSTER | bearish | 5/10 | FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M | Jun 11, 2026 |
| EDIT | INST-CLUSTER | mixed | 5/10 | A mixed institutional cluster in Editas Medicine (EDIT) for Q4 2025 shows quant funds D.E. Shaw and Renaissance Technolo | Jun 11, 2026 |
| RXRX | INST-CLUSTER | neutral | 3/10 | A cluster of five mega-passive institutions (State Street, Wells Fargo, Schwab, Invesco, Morgan Stanley) added $46.3M in | Jun 11, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | Three directors at Recursion Pharmaceuticals sold a total of $271K in open-market transactions over a 7-day window. The | Jun 5, 2026 |
| BNGO | 8-K | bearish | 4/10 | Alka Chaubey, Ph.D., resigned as Chief Medical Officer of Bionano Genomics, effective July 5, 2026. The filing provides | Jun 5, 2026 |
| PACB | 8-K | neutral | 3/10 | Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 2020 Equity Incentive P | Jun 4, 2026 |
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved routine items incl | Jun 4, 2026 |
| FATE | 8-K | neutral | 4/10 | Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli | Jun 4, 2026 |
| ILMN | CLUSTER | neutral | 2/10 | A cluster of insider sales totaling $11.62M occurred over the last week, dominated by Director Keith A. Meister's sale o | Jun 4, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Four insiders at Twist Bioscience sold a total of $1.31M in open-market sales over a 7-day window, including the CEO (vi | Jun 2, 2026 |
| ILMN | CLUSTER | neutral | 3/10 | Three insiders at Illumina (ILMN) sold a total of ~$19.6M in open-market transactions over a 5-day window ending June 1, | Jun 1, 2026 |
| ILMN | CLUSTER | neutral | 2/10 | Two Illumina insiders — the Chief Legal Officer and VP/Chief Accounting Officer — sold a combined $178K in open-market s | Jun 1, 2026 |
| TWST | CLUSTER | neutral | 3/10 | A cluster of insider selling at Twist Bioscience over the past week, led by CEO Emily Leproust who sold ~$3.2M in open-m | Jun 1, 2026 |
| FATE | PRESS-RELEASE | bullish | 6/10 | Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid | Jun 1, 2026 |
| NTLA | PRESS-RELEASE | neutral | 5/10 | Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p | Jun 1, 2026 |
| RXRX | PRESS-RELEASE | neutral | 2/10 | Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 | May 29, 2026 |
| ILMN | COURT-RULING | bearish | 5/10 | A federal magistrate judge in Delaware recommended denying Illumina's motion to dismiss Element Biosciences' patent infr | May 29, 2026 |
| TWST | CLUSTER | bearish | 5/10 | A substantial insider selling cluster at Twist Bioscience, concentrated on May 21-26, 2026, with CEO Emily Leproust alon | May 28, 2026 |
| BNGO | 8-K | bullish | 5/10 | Bionano Genomics fully retired its $20M Senior Secured Convertible Debentures using cash on hand, eliminating all secure | May 28, 2026 |